FDA Clears Automated Segmentation and Quantification Tool for PET Scans

News
Article

The iPETcertum software reportedly provides automated segmentation and enhanced visualization of regions of interest on PET scans with a single click.

The Food and Drug Administration (FDA) has granted 510(k) clearance for the iPETcertum™ software, which offers automated segmentation and improved visualization for positron emission tomography (PET).

While manual segmentation to obtain whole body standardized uptake values (SUVs) and volumes with PET would take hours, iPETcertum provides automated segmentation with one click, according to Claritas NucMed Technologies, the developer of the iPETcertum software.

FDA Clears Automated Segmentation and Quantification Tool for PET Scans

The newly FDA-cleared iPETcertum software offers one-click automated segmentation of PET scans and noise suppression capability that facilitates lower isotope dosing and reduced scan time, according to Claritas NucMed Technologies, the developer of the software. (Image courtesy of Claritas NucMed Technologies.)

In addition to the automated segmentation and quantification capabilities, Claritas NucMed Technologies emphasized the noise suppression benefits with iPETcertum that allow clinicians to obtain quality PET imaging with reduced isotope dosing and/or reduced scan time.

“IPETcertum is a powerful and effective tool that can assist clinicians by removing the (labor)-intensive task of manual segmentation, freeing up our time to focus on diagnostics and decision making. Further, as iPETcertum removes the issue of subjectivity, as it provides values based on uptake values at a voxel level, it can be used as an effective tool for measuring and monitoring of treatment progress over time,” noted Fernando Salis, M.D. Ph.D., the chief medical officer of Claritas NucMed Technologies.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Can Radioligand Therapy Have an Impact for Women with Breast Cancer?
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
© 2025 MJH Life Sciences

All rights reserved.